Stellixir Biotech Private Limited - Due diligence report

A 360° intelligence report on Stellixir Biotech: trust score, financial health, credit view, compliance, directors, growth and distress sign…

2014-09-10 Bangalore, Karnataka Active Unlisted Active Non-Compliant
Share
Connect MCP
SB Stellixir Biotech Private Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Stellixir Biotech — 360° Intelligence Report

Generated from MCA filings & public records
70/100
Trust Score
Moderate

Stellixir Biotech is assessed as Moderate with a Trust Score of 70/100. Stellixir Biotech is an active private limited indian non-government company incorporated in 2014, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 06 Aug 2026 from the latest processed filings. Stellixir Biotech Private Limited snapshot & full profile →

Financial Health › Neutral
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreModerate
70/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
80/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
50/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
80/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreModerate
55/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
95/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
70/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 5 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 80/100 Low Risk
  • Liabilities ≈ 38% EBITDA - serviceable.
  • Profitable - internal accruals available.

Charges position: 1 open (9.50 Lakh) · 0 satisfied (-).

Banking relationships (from registered charges)
LenderChargesAmount
Others1 48.0 cr
Compliance Score: 80/100 Low Risk
  • Company status is Active as per MCA.
  • Marked ACTIVE non-compliant (INC-22A).
  • Annual filings current (balance sheet Mar 2025).
  • 1 active GST registration(s).
05

Director Intelligence

Stability score: 55/100
NameDIN / PANDesignationAppointedTenureDIN status
BEEDAREKERE VEERABHADREGOWDA RAMEGOWDA 01234567 Director 01/04/2018 6 yrs Approved
PAPAYYA BALAKRISHNA JANARDHANA 01234567 Director 01/04/2018 6 yrs Approved
  • 2 directors on the board.
  • BEEDAREKERE VEERABHADREGOWDA RAMEGOWDA has DIN status "Deactivated due to non-filing of DIR-3 KYC".
  • Stable board - no exits in 3 years.
  • Average tenure above 5 years.
Director & KMP remuneration (FY 2021)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2022 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
-
Subsidiaries
-
Group entities
-
Capital events
-

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 95 · Distress 70
Growth signals & trust indicators
Revenue acceleration: +1.42 over 4 year(s).
Latest year revenue grew 2.1x.
Profit expanded 24% year-on-year.
Asset base grew 0.86 - capacity expansion.
Net margin improved to 61%.
Operating for 11+ years.
Active GST registration(s).
Distress signals & risk flags
Negative net worth.
1 open charge(s) registered - assets are encumbered.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence74/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment71/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • 1 open charge(s) of 9.50 Lakh already registered.
  • Compliance record supports lending.
Investor view73/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 5 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management churn warrants questions.
09

MCA Filings & Events Timeline

Latest 6 events
30 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
16 Feb 2015
Charge created
Others - 9.50 Lakh
10 Sep 2014
Incorporated
Registered with Roc Bangalore
Director appointed
BEEDAREKERE VEERABHADREGOWDA RAMEGOWDA (Director)
Director appointed
PAPAYYA BALAKRISHNA JANARDHANA (Director)
10

Key Observations

Auto-generated from the data above
Revenue grew 38% over the last 4 financial year(s).
Net profit margin moved from 1.42 to 2.1x.
Compliance record is strong - status, filings and flags are clean.
2 active director(s) / partner(s); review board churn before relying on management continuity.
1 active GST registration(s) indicate ongoing business operations.
Promoters hold a dominant controlling stake as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Iamps And Hz Technology Solutions Private Limited U74999KA2017PTC104484 Bangalore, Karnataka, India
Innospecs Bioresearch U73100TN2019PTC129205 Chennai, Tamil Nadu, India
Sandu Research Foundation Private Limited U73100GA1994PTC001615 Porvorim, Goa, India
Softinway Digital Engineering Private Limited U72200KA2020PTC135732 Bangalore, Karnataka, India
Times Marine Services Private Limited U74999TN2020PTC138419 Chennai, Tamil Nadu, India
Shree Dhootapapeshwar Ayurvedic Research Foundation U73200MH1996NPL099854 Mumbai, Maharashtra, India
Ott Scientific India Private Limited U51909DL2020FTC364522 New Delhi, Delhi, India
Heorlytics Private Limited U73200PB2021PTC054424 Mohali, Punjab, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Stellixir Biotech before audits and certifications: compliance score 80/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Stellixir Biotech: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 80/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 95/100, margin trends, ownership structure and peer set for Stellixir Biotech - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 70/100, distress signals and MSME payment-delay disclosures - know whether Stellixir Biotech pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (no cases on record), regulatory flags, charge documents trail and director networks for Stellixir Biotech - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Stellixir Biotech an active company?

Stellixir Biotech has MCA status “Active” with a compliance score of 80/100 (Low Risk).

Is Stellixir Biotech financially healthy?

Stellixir Biotech has a Financial Health Score of 50/100 (Moderate) based on its filed financial statements.

Should I do business with Stellixir Biotech?

Its overall Trust Score is 70/100 (Moderate). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Stellixir Biotech?

Promoters hold a dominant controlling stake - exact percentages are in the full report. 2 active director(s) are on record.

Does Stellixir Biotech have loans or charges against its assets?

1 open charge(s) are registered against its assets.

Is Stellixir Biotech up to date with its ROC filings?

Marked ACTIVE non-compliant (INC-22A). Overall compliance score: 80/100 (Low Risk).

Is it risky to lend to Stellixir Biotech?

Its Credit Risk Score is 80/100 (Low Risk). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.